



Mirna Therapeutics Announces Dr. Art Krieg as Scientific Advisor

Austin, Texas, June 15, 2011. Mirna Therapeutics, Inc. ("Mirna") announced today that Arthur M. Krieg, M.D., has joined the Company as a Scientific Advisor.

"We are very pleased about the addition of Dr. Krieg to our team of outstanding Scientific Advisors. Dr. Krieg brings extensive scientific, discovery, and early-stage product development expertise in oligonucleotide therapeutics to Mirna, which will help us craft our research and development plans for the years ahead," said Dr. Paul Lammers, President and Chief Executive Officer of Mirna Therapeutics.

Prior to his current position as an Entrepreneur in Residence at Atlas Ventures, Dr. Krieg served as Chief Scientific Officer of the Oligonucleotide Therapeutics Unit at Pfizer, where he was responsible for Pfizer's RNAi, antisense, and other oligonucleotide-based programs and collaborations. Prior to that, he was CSO, Executive Vice President Research and Development, and co-founder of Coley Pharmaceutical Group, until its acquisition and incorporation into Pfizer in 2008. Dr. Krieg discovered the immune stimulatory CpG DNA motif in 1994, which led to a new approach to immunotherapy and vaccine adjuvants. Based on this technology, he co-founded Coley Pharmaceutical Group in 1997, discovering and taking 4 novel oligonucleotides into clinical development, the most advanced of which is currently in phase 3 trials. Art was a co-founder of the first antisense journal, *Oligonucleotides*, which he edited for 16 years, and he co-founded the Oligonucleotide Therapeutic Society, which today has more than 400 members.

Dr. Krieg graduated from Haverford College in 1979, received his M.D. from Washington University in 1983, and completed a residency in Internal Medicine at the University of Minnesota in 1986. He was a Staff Fellow at the NIH in the Arthritis Institute from 1986 to 1991, before joining the University of Iowa, where he became Professor of Internal Medicine in the Division of Rheumatology. He has published more than 200 scientific papers and is co-inventor on more than 20 issued and 100 pending US patents covering CpG technology.

Dr. Krieg stated, "Mirna's research team began their microRNA efforts in 2002, and since then Mirna has built an impressive understanding of, and collected data on, the critical role that microRNAs play in tumorigenesis and other disease processes, and I am delighted to provide scientific advice to Mirna as they move their lead therapeutic candidates towards the clinic."

About Mirna Therapeutics

Mirna Therapeutics is a biotechnology company focused on the development and commercialization of microRNA (miRNA) therapeutics. The Company has a substantial body of pending intellectual property around miRNAs developed by its own scientists as well as in-licensed from other institutions. Mirna's IP portfolio contains >300 miRNAs with applications in oncology and other diseases. Oncology-directed miRNAs include those that are key tumor suppressors in cancer, such as *miR-34* and *let-7* that have proven to block tumor growth in a number of different pre-clinical animal studies. The Company, founded in 2007, is located in Austin, Texas. For more information, visit www.mirnarx.com.

###

Contact:
Mirna Therapeutics, Inc.
Paul Lammers, M.D., M.Sc.
512.901.0900 or plammers@mirnarx.com